Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man.
Tumor-infiltrating lymphocytes (TILs) are cells generated from tumor suspensions cultured in interleukin 2 that can mediate cancer regression when adoptively transferred into mice or humans. Since TILs proliferate rapidly in vitro, recirculate, and preferentially localize at the tumor site in vivo, they provide an attractive model for delivery of exogenous genetic material into man. To determine whether efficient gene transfer into TILs is feasible, we transduced human TILs with the bacterial gene for neomycin-resistance (NeoR) using the retroviral vector N2. The transduced TIL populations were stable and polyclonal with respect to the intact NeoR gene integration and expressed high levels of neomycin phosphotransferase activity. The NeoR gene insertion did not alter the in vitro growth pattern and interleukin 2 dependence of the transduced TILs. Analyses of T-cell receptor gene rearrangement for beta- and gamma-chain genes revealed the oligoclonal nature of the TIL populations with no major change in the DNA rearrangement patterns or the levels of mRNA expression of the beta and gamma chains following transduction and selection of TILs in the neomycin analog G418. Human TILs expressed mRNA for tumor necrosis factors (alpha and beta) and interleukin 2 receptor P55 but not for interleukin 1 beta, granulocyte/macrophage colony-stimulating factor, interleukin 6, and interferon gamma when grown with high-dose interleukin 2 without subsequent activation with mitogen or specific antigen. This pattern of cytokine-mRNA expression was not significantly altered following the transduction of TILs. The NeoR gene-transduced TILs could thus be used to follow the trafficking and survival of TILs in vivo, and clinical protocols using these transduced TILs in cancer patients have begun. The studies demonstrate the feasibility of TILs as suitable cellular vehicles for the introduction of therapeutic genes into patients receiving autologous TILs.
Kasid
A
A
Surgery Branche, National Cancer Institute, Bethesda, MD 20892.
Morecki
S
S
Aebersold
P
P
Cornetta
K
K
Culver
K
K
Freeman
S
S
Director
E
E
Lotze
M T
MT
Blaese
R M
RM
Anderson
W F
WF
D001685:Biological Factors / Q000235:genetics; D015152:Blotting, Northern; D002455:Cell Division; D002460:Cell Line; D016207:Cytokines; D015870:Gene Expression; D015329:Gene Rearrangement, T-Lymphocyte; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007116:Immunization, Passive; D008214:Lymphocytes / Q000473:pathology / Q000502:physiology*; D008545:Melanoma / Q000628:therapy*; D012333:RNA, Messenger / Q000235:genetics; D015375:Receptors, Interleukin-2 / Q000235:genetics; D012190:Retroviridae / Q000235:genetics*; D013601:T-Lymphocytes / Q000276:immunology; D014161:Transduction, Genetic; D014162:Transfection; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D001685:Biological Factors; D016207:Cytokines; D012333:RNA, Messenger; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha